Lumos Pharma, Inc. (LUMO): Price and Financial Metrics


Lumos Pharma, Inc. (LUMO)

Today's Latest Price: $18.47 USD

0.79 (-4.10%)

Updated Jan 26 4:00pm

Add LUMO to Watchlist
Sign Up

Overall POWR Rating


POWR Components:

 Trade Grade  Buy & Hold Grade  Peer Grade  Industry Rank


Industry Rank:

Ranked of 484 in Biotech

See all "A" rated Strong Buy stocks

LUMO Stock Summary

  • The ratio of debt to operating expenses for Lumos Pharma Inc is higher than it is for about just 5.54% of US stocks.
  • With a price/sales ratio of 284.85, Lumos Pharma Inc has a higher such ratio than 98.11% of stocks in our set.
  • With a year-over-year growth in debt of -71.31%, Lumos Pharma Inc's debt growth rate surpasses only 3.66% of about US stocks.
  • Stocks that are quantitatively similar to LUMO, based on their financial statements, market capitalization, and price volatility, are OPTT, LCTX, AIM, EDSA, and SWAV.
  • LUMO's SEC filings can be seen here. And to visit Lumos Pharma Inc's official web site, go to www.lumos-pharma.com.

LUMO Stock Price Chart Interactive Chart >

Price chart for LUMO

LUMO Price/Volume Stats

Current price $18.47 52-week high $36.72
Prev. close $19.26 52-week low $6.74
Day low $17.60 Volume 41,357
Day high $19.50 Avg. volume 54,544
50-day MA $20.47 Dividend yield N/A
200-day MA $15.50 Market Cap 153.25M

Lumos Pharma, Inc. (LUMO) Company Bio


Lumos Pharma, Inc. operates as a biopharmaceutical company. The Company discovers, develops, and commercializes therapeutics for patients and families living with rare diseases. Lumos Pharma operates worldwide.

LUMO Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$18.47$0.68 -96%

Below please find a table outlining a discounted cash flow forecast for LUMO, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Lumos Pharma Inc ranked in the 7th percentile in terms of potential gain offered. Our DCF analysis suggests the stock is overvalued by about 96.33%. In terms of the factors that were most noteworthy in this DCF analysis for LUMO, they are:

  • The company's compound free cash flow growth rate over the past 5.51 years comes in at -0.37%; that's greater than only 3.96% of US stocks we're applying DCF forecasting to.
  • Relative to other stocks in its sector (Healthcare), Lumos Pharma Inc has a reliance on debt greater than just 6.67% of them.


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%-97%
1%-97%
2%-96%
3%-96%
4%-96%
5%-96%

INFU, NVST, PHG, PPD, and SXTC can be thought of as valuation peers to LUMO, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.


LUMO Latest News Stream


Event/Time News Detail
Loading, please wait...

LUMO Latest Social Stream


Loading social stream, please wait...

View Full LUMO Social Stream

Latest LUMO News From Around the Web

Below are the latest news stories about Lumos Pharma Inc that investors may wish to consider to help them evaluate LUMO as an investment opportunity.

Lumos Pharma to Participate in the H.C. Wainwright BioConnect 2021 Conference

AUSTIN, Texas, Dec. 18, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that the company will participate in the virtual H.C. Wainwright BioConnect 2021 Conference to be held January 11-14, 2021.H.C. Wainwright BioConnect 2021 Conference    Date:January 11, 2021    What:Lumos Pharma Presentation   A webcast of Lumos Pharma’s presentation will be available on-demand as of 6:00AM ET, Monday, January 11, 2021, through the H.C. Wainwright conference portal and on Lumos Pharma’s website under “Events & Presentations” in the Investors & Media section.  The webcast will be available on Lumos Pharma’s website for 30 days. No one-on-one meetings will be held at the presentation - o...

Yahoo | December 18, 2020

What You Need To Know About Lumos Pharma, Inc.'s (NASDAQ:LUMO) Investor Composition

If you want to know who really controls Lumos Pharma, Inc. ( NASDAQ:LUMO ), then you'll have to look at the makeup of...

Yahoo | December 16, 2020

Is Lumos Pharma (LUMO) A Good Stock To Buy Now?

Hedge funds and large money managers usually invest with a focus on the long-term horizon and, therefore, short-lived dips or bumps on the charts usually don’t make them change their opinion towards a company. This time it may be different. The coronavirus pandemic destroyed the high correlations among major industries and asset classes. We are […]

Yahoo | November 30, 2020

Lumos Pharma Announces the Initiation of Phase 2b OraGrowtH210 Trial and Reports Third Quarter 2020 Financial Results

* Lumos Pharma has initiated Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency (PGHD) patients with data read-out anticipated mid-year 2022 AUSTIN, Texas, Nov. 10, 2020 (GLOBE NEWSWIRE) -- Lumos Pharma, Inc. (NASDAQ:LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced financial results for the third quarter ended September 30, 2020 and provided an update on clinical activities.“This past quarter was marked by significant achievements leading to the initiation of our Phase 2b OraGrowtH210 Trial evaluating oral LUM-201 in pediatric growth hormone deficiency patients and the previously announced sale of our PRV in July,” commented Rick Hawkins, Chairman, CEO and President of Lumos Pharma. “We are th...

Yahoo | November 10, 2020

Lumos Pharma Inc to Host Earnings Call

NEW YORK, NY / ACCESSWIRE / November 10, 2020 / Lumos Pharma Inc (NASDAQ:LUMO) will be discussing their earnings results in their 2020 Third Quarter Earnings call to be held on November 10, 2020 at 4:30 PM Eastern Time.

Yahoo | November 10, 2020

Read More 'LUMO' Stories Here

LUMO Price Returns

1-mo N/A
3-mo 29.16%
6-mo 31.83%
1-year 20.01%
3-year -76.08%
5-year -91.45%
YTD -48.28%
2020 56.83%
2019 66.45%
2018 -81.26%
2017 -21.11%
2016 -71.75%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!



Page generated in 0.9044 seconds.